AssetMark’s Bicara Therapeutics BCAX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCAX
SL
JHC
AssetMark's BCAX Position: Q3 2026 in Review
AssetMark opened a new position in Bicara Therapeutics (BCAX) in Q3 2026: 25 shares worth $465. The stake represents ﹤0.01% of the portfolio and ranks #3428 among its holdings.
114 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.
- AssetMark held 25 shares of Bicara Therapeutics worth $465 as of Q3 2026.
- Bicara Therapeutics was a new AssetMark position in Q3 2026.
- Bicara Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3428 holding.
- 114 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.